The Annual FDA/PhUSE Computational Science Symposium, to be held on March 18th and 19th 2013 in
Silver Spring, Maryland, provides the premier forum for industry and FDA to collaborate in the realm of
computational science.
PhUSE, an independent, non‐profit community of professionals focused around the advancement of clinical
information is proud to co‐sponsor, along with The Food and Drug Administration, the Annual FDA/PhUSE
Computational Science Symposium, to be held on March 18th and 19th 2013 in Silver Spring, Maryland, USA.
The symposium is an opportunity for FDA, the pharmaceutical industry, academia, and other computational
science stakeholders to meet in a collaborative environment.
“The symposium provides a platform for FDA and industry to collaborate with the goal of closing some of the
gaps we face in delivering information to the FDA and solving the challenges FDA deals with during their
review cycle,” says Chris Decker, PhUSE FDA Liaison and Vice President, Life Sciences Practice at d‐Wise.
A vital part of the stakeholder collaboration resulted from the creation of working groups at the annual
symposium in 2012. The working group areas of focus are: Data Quality, Data Standards, Standard Scripts,
Non‐clinical. The 2013 Symposium will provide a venue for these groups to continue their collaborative efforts,
as well as to share the exciting progress that they have made in 2012. Additional projects are being formed to
address increasing challenges to the access and review of data identified since the previous meeting.
Participants are encouraged to submit abstracts for a poster session at the Symposium. Abstracts are due by
January 31st 2013.
The Symposium will be held at the Silver Spring Civic Building at Veterans Plaza.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.